1. Home
  2. XXII vs ENTO Comparison

XXII vs ENTO Comparison

Compare XXII & ENTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XXII
  • ENTO
  • Stock Information
  • Founded
  • XXII 1998
  • ENTO 2014
  • Country
  • XXII United States
  • ENTO United States
  • Employees
  • XXII N/A
  • ENTO N/A
  • Industry
  • XXII Medicinal Chemicals and Botanical Products
  • ENTO Biotechnology: Pharmaceutical Preparations
  • Sector
  • XXII Health Care
  • ENTO Health Care
  • Exchange
  • XXII Nasdaq
  • ENTO Nasdaq
  • Market Cap
  • XXII 2.0M
  • ENTO 2.3M
  • IPO Year
  • XXII N/A
  • ENTO 2016
  • Fundamental
  • Price
  • XXII $1.75
  • ENTO $4.50
  • Analyst Decision
  • XXII
  • ENTO
  • Analyst Count
  • XXII 0
  • ENTO 0
  • Target Price
  • XXII N/A
  • ENTO N/A
  • AVG Volume (30 Days)
  • XXII 153.3K
  • ENTO 175.1K
  • Earning Date
  • XXII 11-11-2025
  • ENTO 11-12-2025
  • Dividend Yield
  • XXII N/A
  • ENTO N/A
  • EPS Growth
  • XXII N/A
  • ENTO N/A
  • EPS
  • XXII N/A
  • ENTO N/A
  • Revenue
  • XXII $21,362,000.00
  • ENTO N/A
  • Revenue This Year
  • XXII $22.41
  • ENTO N/A
  • Revenue Next Year
  • XXII $76.35
  • ENTO N/A
  • P/E Ratio
  • XXII N/A
  • ENTO N/A
  • Revenue Growth
  • XXII N/A
  • ENTO N/A
  • 52 Week Low
  • XXII $1.59
  • ENTO $0.93
  • 52 Week High
  • XXII $978.08
  • ENTO $5.20
  • Technical
  • Relative Strength Index (RSI)
  • XXII 30.34
  • ENTO 82.41
  • Support Level
  • XXII $1.68
  • ENTO $2.25
  • Resistance Level
  • XXII $1.86
  • ENTO $2.95
  • Average True Range (ATR)
  • XXII 0.09
  • ENTO 0.50
  • MACD
  • XXII 0.13
  • ENTO 0.20
  • Stochastic Oscillator
  • XXII 56.78
  • ENTO 87.90

About XXII 22nd Century Group Inc.

22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.

About ENTO Entero Therapeutics Inc. Common Stock

Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: